CorneaGen is planning to eliminate corneal blindness through research, products, therapeutics, prevention, and policy to transform the corneal ecosystem.
Orasis product, CSF-1 is an eye drop currently in clinical development to treat presbyopia. Delivered as a topical solution directly to the eyes, CSF-1 contains a proprietary combination of existing and well-known components with the potential to restore vision in people with presbyopia.
Transforming the lens industry by being able to optimize a lens after implantation. RxSight has developed breakthrough intraocular lens technology for use in cataract and lens replacement surgery. Designed by a Nobel Prize winning scientist, RxSights’s Light Adjustable Lens (RxLAL) utilizes light to enable physicians to make office-based refractive adjustments after it has been implanted in the eye.